Our work

Vardis Supports Fine Industries & NorthEdge

Vardis is proud to support Fine Industries and NorthEdge in its appointment of Chris Gowland as CEO.


Fine Industries, a Teesside-based manufacturer of chemicals for use in crop protection, pharmaceutical and speciality markets, has appointed a new Chief Executive, Chris Gowland.

Chris was a founding member of the Aesica management team in 2004 and has held a number of key roles on the executive team including Chief Operating Officer. He was also a board member for Aesica LLC and the President of Aesica Srl.

Chris said: "Fine Industries has been through a substantial period of growth. I am looking forward to working with customers and staff to build further on the platform that has already been created, and hopefully to take advantage of further growth opportunities."

Fine Industries Chairman, Brian Davidson, added: "I am delighted that we have secured the involvement of one of the top operators in the industry. "Chris will bring a combination of operational excellence and strategic business development skills to Fine Industries and we are delighted that he is coming to join us at this exciting time of our continued development”.

Earlier this year, Fine Industries secured a place in the Sunday Times BDO Profit Track 100. Fine Industries manufactures high quality fine chemicals for use in the crop protection, pharmaceutical and specialty chemicals markets. Founded in 1977, the business employs 270 staff with a turnover of £40million for the year ended 30 September 2013. It has an international blue chip client base and exports to countries including Switzerland, Germany, USA, Brazil and Ireland.

NorthEdge manages a £225 million private equity fund aimed at lower mid-market buy-out and development capital transactions. They look to invest in like-minded businesses and management teams who have real ambition and the potential to shape global markets from the North of England. NorthEdge Capital,  backed Fine Industries, a Teesside-based manufacturer of fine chemicals in 2013. The £25.5million investment will accelerate the capital expenditure programme to increase capacity and support the company’s growth ambitions. 

Related Articles

Our global offices